Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Switching from tobacco to e-cigarettes improves vascular health

29 Dec 2019

Vascular health has significantly improved within 1 month of switching from tobacco cigarette (TC) to e-cigarette (EC), particularly in females, a study has shown. Switching from TC to EC may thus be regarded as a harms reduction measure.

This prospective, randomized controlled trial with a parallel nonrandomized preference cohort and blinded endpoint included smokers aged ≥18 years who had smoked ≥15 cigarettes/day for ≥2 years and were free from established cardiovascular disease. They were randomly assigned to EC with or without nicotine for 1 month. Those unwilling to quit continued with TC in a parallel preference arm.

The authors performed a propensity-score analysis to adjust for differences between the randomized and preference arms. They then assessed vascular function by flow-mediated dilation (FMD) and pulse wave velocity. Carbon monoxide levels were used to measure compliance with EC.

A significant improvement was achieved within 1 month of switching from TC to EC in endothelial function (linear trend β, 0.73 percent, 95 percent confidence interval [CI], 0.41–1.05; p<0.0001; TC vs EC combined: 1.49 percent, 95 percent CI, 0.93–2.04; p<0.0001) and vascular stiffness (−0.529 m/s, 95 percent CI, −0.946 to −0.112; p=0.014).

In every between-group comparison, females benefitted more than males from switching to EC, and those with the best compliance to the EC switch showed the largest improvement. Moreover, no difference was seen in vascular effects between EC with and without nicotine within the study timeframe.

“Meta-analysis of FMD studies indicate 13-percent lower pooled, adjusted relative risks of cardiovascular events with every 1-percent improvement in FMD,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.